Gain critical insights by using ctDNA testing with exquisite sensitivity
Purpose-built technology for oncologists, developed by pioneers of cancer research
Haystack MRD was developed by researchers who understand the importance of providing accurate data for confident treatment decisions. Our ctDNA testing uncovers the insights you need to make confident decisions compared to traditional methods for cancer treatment when answering patients’ most pressing postsurgery questions:
Did my treatment work?
Go beyond standard risk assessment for adjuvant chemotherapy to help guide the right treatment for the right person at the right time.
Do I need additional therapy?
Track ctDNA levels during adjuvant chemotherapy or second-line therapy to monitor treatment response.
Is the cancer coming back?
Limit of detection of 0.0006% tumor fraction to help identify recurrence earlier than traditional methods so you can intervene sooner.
Why test for ctDNA?
Circulating tumor DNA (ctDNA) detection is a noninvasive method to assess tumor burden with a blood sample. Recent data also correlate ctDNA levels in postsurgical cancer patients with recurrence-free survival (RFS) and risk of recurrence.
3-yr RFS*
3-yr RFS*
more likely to recur
*Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92. doi:10.1126/scitranslmed.aaf6219
Haystack MRD is personalized for each patient. Tumor tissue collected at surgery is sent to Quest Diagnostics for whole-exome sequencing (WES) to identify patient-specific somatic mutations. A personalized MRD test targeting up to 50 of these mutations is then developed to detect ctDNA in a blood sample. The MRD test can then be performed whenever needed to detect residual or recurrent disease throughout the patient’s care journey.
Haystack MRD is purpose-built for ultra-sensitive ctDNA detection in patients with solid tumors and can be used to detect residual disease to guide adjuvant therapy, to monitor treatment response, and for recurrence surveillance.
DYNAMIC is the first interventional, random-controlled trial to demonstrate a significant clinical benefit to utilizing MRD testing to guide adjuvant therapy in early-stage solid tumor patients. Powered by a highly optimized version of the technology employed in DYNAMIC, Haystack MRD is rooted in demonstrated clinical utility.
Exquisite sensitivity to enhance your expertise
Haystack MRD’s technology enables ultrasensitive ctDNA testing with the ability to detect 95% of cases at 0.0006% tumor fraction. With such a low limit of detection, you can uncover the insights you need to help you make earlier and more confident treatment decisions.
With greater sensitivity, more patients who are at higher risk of recurrence can be identified. Therefore, patients with relapse may be identified at an earlier stage, when treatment is more likely to be successful.
Better sensitivity means molecular recurrence can be detected at lower levels and with greater lead time in advance of clinical recurrence compared to other methods.
With an error rate that is 100x lower than other methods, Haystack MRD delivers confidence in ctDNA results.
